Higher scores correspond to a greater need for transplantation and other treatments.
Addition of assigned points, as above.
Facts & Figures
|Total Risk Score||Expected 1-year probability of death|
Original/Primary Referencedu Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.2011;184:459–66. doi: 10.1164/rccm.201011-1790OC.
Validationdu Bois RM, et. al. Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2011 184:12, 1382-1389.
Other ReferencesKolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future Eur Respir Rev 2014; 23: 220–224.Wilkie MEM, Chalmers JD, Smith RP, Schembri S. Asthma outcomes: P134 Comparison of Two Prognostic Tools For Identifying High Risk Patients with Idiopathic Pulmonary Fibrosis. Thorax 2012;67:Suppl 2 A120 doi:10.1136/thoraxjnl-2012-202678.417
About the Creator
Roland M. Dubois, MD, is a professor of respiratory medicine and senior research investigator at Imperial College in London. Previously, he was a professor at National Jewish Health in Denver and Consultant Physician at the Royal Brompton Hospital. Dr. du Bois advises on studies of innovative therapy for idiopathic pulmonary fibrosis and conducts research on genetics, pathogenesis and treatment of interstitial lung diseases.
To view Dr. Roland du Bois's publications, visit PubMed